Answers are grounded in this paper and cite their sources.
The ongoing coronavirus disease 2019 (COVID‐19) pandemic and other major viral infectious diseases have become a significant threat to people's life and economic/social development. In recent years, with the development of nanotechnology, nanomaterial‐based antiviral agents have been extensively studied. However, the clinical applications of antiviral nanomaterials are still limited. Herein, the recent advances in nanomaterial‐based antiviral strategies, mainly including antiviral nanodrugs, drug nanocarriers, and nanovaccines, are summarized. The clinical challenges and prospects of nanomaterial‐based antiviral strategies are also discussed.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: